-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites with total capacity of 4000L, with further expansion opportunities -- --...

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the 39th Annual J.P....

REDWOOD CITY, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent...

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32nd...

-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after a single IVT injection of ADVM-022 -- -- Robust preliminary aqueous anti-VEGF protein expression observed at 18 months in Cohort 1 – -- Well tolerated with ocular cell grades and steroid...

-- Company to host conference call and webcast with KOLs to discuss new data from Cohorts 1-4 of OPTIC Phase 1 trial of ADVM-022 for wet AMD on November 14, 2020 at 7:30 am PT -- -- FDA removes partial clinical hold on ADVM-022 -- -- Planning to start a pivotal...

-- Dr. Carl Regillo to present OPTIC data at the Retina Subspecialty Day on Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday, November 14, 2020 at 7:30 am PT -- REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE...

REDWOOD CITY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Christopher J. Morrison, Ph.D. joined the...

REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual...

REDWOOD CITY, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten...